子宫动脉栓塞与氨甲环酸方案在胎盘植入谱系疾病中的实施与结局
本研究对2018-2022年产前疑似胎盘植入/穿透性植入患者实施子宫动脉栓塞联合氨甲环酸方案,并与2013-2017年未实施方案组比较。结果显示方案组手术时间延长、全身麻醉比例更高,但出血量减少33%、总体输血率降低51%、大量输血减少5倍,术后并发症率和新生儿结局无差异。
要点
- 方案组手术时间416分钟 vs 未方案组187分钟(P<.01),全身麻醉比例80% vs 47%(P<.01)。
- 方案组出血量2000 cc vs 未方案组3000 cc,减少33%(P=.03)。
- 方案组总体输血率降低51%(OR 0.05,95%CI 0.001-0.20;P<.01),大量输血(>10单位)减少5倍(OR 0.17,95%CI 0.02-0.17;P=.02)。
核心结论
- 子宫动脉栓塞与氨甲环酸方案是标准化复杂胎盘植入谱系病例的有效方法,可优化围手术期结局并降低孕产妇发病率。
研究设计与样本
- 本研究为实施方案前后对比分析,纳入产前疑似胎盘植入/穿透性植入患者,方案实施期为2018-2022年共5年,对照期为2013-2017年共5年。
- 10年间胎盘植入谱系团队共管理126例,其中66例疑似胎盘植入/穿透性植入;方案实施后队列中2例因未接受两种干预被排除,最终方案组30例(30/64;47%),未方案组34例(34/64;53%)。
- 患者人口学资料和临床相关结局取自电子病历。
主要发现
- 方案组手术时间更长(416 vs 187分钟;P<.01),全身麻醉比例更高(80% vs 47%;P<.01)。
- 方案组出血量减少33%(2000 vs 3000 cc;P=.03)。
- 方案组总体输血率降低51%(OR 0.05,95%CI 0.001-0.20;P<.01)。
- 方案组大量输血(>10单位)减少5倍(OR 0.17,95%CI 0.02-0.17;P=.02)。
- 术后并发症事件数两组无显著差异(4 vs 10;P=.14),新生儿结局等效。
临床怎么用
- 原文结论认为该方案是标准化复杂胎盘植入谱系病例的有效方法,可优化围手术期结局并降低孕产妇发病率。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Placenta accreta spectrum disorders are a continuum of placental pathologies with significant maternal morbidity and mortality. Morbidity is related to the overall degree of placental adherence, and thus patients with placenta increta or percreta represent a high-risk category of patients. Hemorrhage and transfusion of blood products represent 90% of placenta accreta spectrum morbidity. Both tranexamic acid and uterine artery embolization independently decrease obstetrical hemorrhage. OBJECTIVE: This study aimed to provide an evidence-based intraoperative protocol for placenta accreta spectrum management. STUDY DESIGN: This study was a pre- and postimplementation analysis of concomitant uterine artery embolization and tranexamic acid in cases of patients with antenatally suspected placenta increta and percreta over a 5-year period (2018-2022). For comparison, a 5-year (2013-2017) preimplementation group was used to assess the impact of the uterine artery embolization and tranexamic acid protocol for placenta accreta spectrum. Patient demographics and clinically relevant outcomes were obtained from electronic medical records. RESULTS: A total of 126 cases were managed by the placenta accreta spectrum team, of which 66 had suspected placenta increta/percreta over the 10-year time period. Two patients were excluded from the postimplementation cohort because they did not undergo both interventions. Thus, 30 (30/64; 47%) were treated after implementation of the uterine artery embolization and tranexamic acid protocol for placenta accreta spectrum, and 34 (34/64; 53%) preimplementation patients did not undergo uterine artery embolization or tranexamic acid infusion. With the uterine artery embolization and tranexamic acid protocol, operative times were longer (416 vs 187 minutes; P<.01), and patients were more likely to receive general anesthesia (80% vs 47%; P<.01). However, blood loss was reduced by 33% (2000 vs 3000 cc; P=.03), overall blood transfusion rates decreased by 51% (odds ratio, 0.05 [95% confidence interval, 0.001-0.20]; P<.01), and massive blood transfusion (>10 units transfused) was reduced 5-fold (odds ratio, 0.17 [95% confidence interval, 0.02-0.17]; P=.02). Postoperative complication rates remained unchanged (4 vs 10 events; P=.14). Neonatal outcomes were equivalent. CONCLUSION: The uterine artery embolization and tranexamic acid protocol for placenta accreta spectrum is an effective approach to the standardization of complex placenta accreta spectrum cases that results in optimal perioperative outcomes and reduced maternal morbidity.
引用
- Munoz JL, Blankenship LM, Ramsey PS, et al. Implementation and outcomes of a uterine artery embolization and tranexamic acid protocol for placenta accreta spectrum. Am J Obstet Gynecol. 2023. PMID: 36965865. doi:10.1016/j.ajog.2023.03.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。